What is Halozyme Therapeutics's D&A?

Halozyme Therapeutics (HALO) reported D&A of $4.22M in Q1 2026.

How has Halozyme Therapeutics's D&A changed year-over-year?

Halozyme Therapeutics's D&A increased by 57.1% year-over-year, from $2.69M to $4.22M.

What is the long-term trend for Halozyme Therapeutics's D&A?

Over 4 years (2021 to 2025), Halozyme Therapeutics's D&A has grown at a 39.5% compound annual growth rate (CAGR), from $3.01M to $11.39M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Halozyme Therapeutics HALO D&A

D&A at other companies

West Pharmaceutical ServicesWST

$44.6M+14.1%

BridgeBio PharmaBBIO

$1.19M-7.6%

Arrowhead ResearchARWR

$6.37M+4.7%

AptarGroupATR

$64.31M+17.1%

AlkermesALKS

$19.43M+162%

LQD

Liquidia CorporationLQDA

——

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's D&A?: Halozyme Therapeutics (HALO) reported D&A of $4.22M in Q1 2026.
How has Halozyme Therapeutics's D&A changed year-over-year?: Halozyme Therapeutics's D&A increased by 57.1% year-over-year, from $2.69M to $4.22M.
What is the long-term trend for Halozyme Therapeutics's D&A?: Over 4 years (2021 to 2025), Halozyme Therapeutics's D&A has grown at a 39.5% compound annual growth rate (CAGR), from $3.01M to $11.39M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.